By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Teijin Ltd. et al. v. Unimark Remedies Ltd.
1:14-cv-01356; filed November 4, 2014 in the District Court of Delaware
• Plaintiffs: Teijin Ltd.; Teijin Pharma Ltd.; Takeda Pharmaceuticals USA Inc.
• Defendant: Unimark Remedies Ltd.
Infringement of U.S. Patent No. 7,361,676 ("Solid Preparation Containing Single Crystal Form," issued April 22, 2008) following a Paragraph IV certification as part of Unimark's filing of an ANDA to manufacture a generic version of Takeda's Uloric® (febuxostat, used for the chronic management of hyperuricemia in patients with gout). View the complaint here.
Senju Pharmaceutical Co., Ltd. et al. v. Innopharma Licensing, Inc. et al.
1:14-cv-06893; filed November 3, 2014 in the District Court of New Jersey
• Plaintiffs: Senju Pharmaceutical Co., Ltd.; Bausch & Lomb, Inc.; Bausch & Lomb Pharma Holdings Corp.
• Defendants: Innopharma Licensing, Inc.; Innopharma Licensing, LLC; Innopharma, Inc.; Innopharma, LLC
Infringement of U.S. Patent Nos. 8,129,431 ("Aqueous Liquid Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid," issued March 6, 2012), 8,669,290 (same title, issued March 1, 2014), 8,754,131 (same title, issued June 17, 2014), and 8,871,813 (same title, issued October 28, 2014) following a Paragraph IV certification as part of Innopharma's filing of an ANDA to manufacture a generic version of B&L's Prolensa® (bromfenac ophthalmic solution, used to treat postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery). View the complaint here.
AstraZeneca AB v. Actavis Laboratories FL Inc. et al.
1:14-cv-01356; filed October 31, 2014 in the District Court of Delaware
• Plaintiff: AstraZeneca AB
• Defendants: Actavis Laboratories FL Inc.; Watson Laboratories Inc.; Actavis Inc.; Actavis LLC
Infringement of U.S. Patent Nos. RE44,186 ("Cyclopropyl-Fused Pyrrolidine-Based Inhibitors of Dipeptidyl Peptidase IV and Method," issued April 30, 2013) and 8,628,799 (same title, issued January 14, 2014) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of AstraZeneca's Kombiglyze XR (saxagliptin and metformin hydrochloride, extended-release, used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus). View the complaint here.
Otsuka Pharmaceutical Co., Ltd. v. Aurobindo Pharma Ltd. et al.
1:14-cv-06890; filed October 31, 2014 in the District Court of New Jersey
• Plaintiff: Otsuka Pharmaceutical Co., Ltd.
• Defendants: Aurobindo Pharma Ltd.; Aurobindo Pharma USA, Inc.; Aurolife Pharma LLC
Infringement of U.S. Patent No. 8,759,350 ("Carbostyril Derivatives and Serotonin Reuptake Inhibitors for Treatment of Mood Disorders," issued June 24, 2014) following a Paragraph IV certification as part of Aurobindo's filing of an ANDA to manufacture a generic version of Otsuka's Abilify® (aripiprazole, used to treat bipolar disorder and schizophrenia). View the complaint here.
Comments